NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line Treatment

Earn CME credit for this activity: https://www.naccme.com/program/2018-802-02

This on-demand webcast examines the efficacy and safety, indications, and cost utility of available EGFR tyrosine kinase inhibitors (TKIs) and monoclonal antibodies into optimal first-line selection and NSCLC pathway placement strategies.

© 2018 NACCME, an HMP Company